This week in health equity and access: Medicaid cuts; mailed FIT outreach; EEOC pregnancy rules; GLP-1 Bridge access; and 2027 policy shifts.
News|Articles|May 13, 2026
5 Key Regulatory Shifts From Makary's Era at the FDA
Author(s)Pearl Steinzor
Fact checked by: Laura Joszt, MA
From rewriting drug approval standards to embedding AI in review workflows, former FDA commissioner Marty Makary, MD reshaped how evidence, speed, and access are balanced in US drug regulation.
Advertisement
Advertisement
The FDA has undergone a series of major policy shifts under Marty Makary, MD, MPH, who recently
Related to this article
Why artificial intelligence in health care falls short today and how implementing technology in health care requires integrated workflows to cut costs and improve outcomes.
The EEOC is reportedly preparing to narrow Pregnant Workers Fairness Act rules; no revised rule has been published as of yet.
Phase 3 Viti-Up trials show Rinvoq (upadacitinib) JAK inhibitor boosts facial and body repigmentation in nonsegmental vitiligo, with familiar safety.
Machine learning prediction of procalcitonin positivity using inexpensive routine laboratory tests may reduce procalcitonin test volume and support diagnostic stewardship.
A population-based study of 1102 Canadian children found infants with bone and soft tissue tumors had poorer survival, driven largely by treatment deaths.
Liver disease disparities tied to insurance and race spanned HCC surveillance, transplant listing, and drug access in data at The Liver Meeting 2026.
A case report describes the first KRAS::ETNK1 fusion in MDS/MPN with eosinophilia; the fusion disappeared when disease relapsed as AML after transplant.
Advertisement
Advertisement